Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
1001202-16-9
141743-15-9
156939-62-7
180576-05-0
181952-29-4
204320-65-0
36603-49-3 | 2-(4-Bromophenoxy)tetrahydropyran | AA00I76G | MFCD00091551
376387-68-7 | 1H-Pyrazole-3-carboxylic acid, 1-(1,1-dimethylethyl)-5-methyl- | AA00I7C4 | MFCD01313628
383130-76-5 | 5-(3-Phenoxy-phenyl)-[1,3,4]thiadiazol-2-ylamine | AA00I7HR | MFCD02664102
392660-50-3 | 8-Bromo-5-methoxy-1,2,3,4-tetrahydroisoquinoline | AA00I7O4 | MFCD18306473
40246-10-4 | Glycitin | AA00I7TI | MFCD00800711
41337-81-9 | Ethyl 6-(hydroxymethyl)pyridine-2-carboxylate | AA00I80C | MFCD09750009
42438-89-1 | Pinostilbene | AA00I84Z | MFCD12407153
4385-35-7 | 3-Isochromanone | AA00I8A4 | MFCD00043005
4602-36-2 | 3-Phenyl-1,4-diazaspiro[4.5]dec-3-ene-2-thione | AA00I8H7 | MFCD02311198
478553-83-2 | 2-Methyl-4-nitro-1,3-benzoxazole | AA00I8MX | MFCD08064696